Objective To examine the association of the APOE e2e4 genotype with incident Alzheimer disease (AD), mild cognitive impairment (MCI), cognitive decline, and AD pathology in older adults.
The APOE gene is the best known genetic risk factor for lateonset Alzheimer disease (AD). It has 3 common alleles, e2, e3, and e4. Prior work has shown that e4 carriers (e4e4 or e3e4) are associated with about a 3-fold increased risk of AD dementia, 1 more rapid cognitive decline, 1 and a higher burden of AD pathology. 2 By contrast, e2 carriers (e2e2 or e2e3) are associated with a decreased risk of AD dementia, 3 slower cognitive decline, 4 and lower burden of AD pathology. 5 Prior studies have generally excluded the small number of individuals with the e2e4 genotype, or have included few e2e4 carriers without specific analyses for their association with AD dementia. Therefore, the association of e2e4 genotype with cognitive function and AD pathology in older adults is unknown.
Prior work from our group mostly excluded persons with APOE e2e4. 6 In this study, we used data from communitydwelling older adults of European ancestry participating in the Religious Orders Study (ROS) or the Rush Memory and Aging Project (MAP) who were free of dementia at baseline and underwent structured annual clinical evaluation. We examined the associations of APOE e2e4 with incident AD dementia, incident mild cognitive impairment (MCI), the rate of cognitive decline, and in decedents, measures of AD pathology.
Methods
Participants Participants were enrolling in 2 ongoing cohort studies in which they agreed to annual assessments and brain donation at the time of death. ROS began in 1994 and has been recruiting older nuns, priests, and brothers from more than 45 sites across the United States. 7 MAP began in 1997, and has been enrolling residents from retirement facilities and subsidized housings across the Chicago metropolitan area. 8 Uniform data collection and autopsy procedures conducted by the same team allow us to analyze ROS and MAP data together. The overall follow-up exceeds 90%, and the combined autopsy rate for both studies exceeds 85%. The association of APOE with AD varies in different ethnic groups, 3 so we limited our analyses to non-Latino white. At the time of these analyses, 2,151 ROS and MAP participants had completed baseline evaluations and did not have clinical dementia, had valid APOE genotyping, and had at least one valid followup examination to allow for longitudinal analyses.
Assessment of cognition and clinical diagnoses
Participants underwent a uniform structured annual clinical examination, which included 21 cognitive tests. Standardized scores of 7 tests were combined to create an episodic memory score, 3 tests used for semantic memory, 3 tests for working memory, 2 tests for perceptual speed, and 2 tests for visuospatial abilities. All 17 tests were summarized into a global cognition score as previously described. 9 A neuropsychologist and neurologist with expertise in dementia reviewed annual findings and classified cognitive status as no cognitive impairment (NCI), MCI, probable and possible AD, and other dementias. 10 APOE genotyping DNA was extracted from peripheral blood lymphocytes or frozen postmortem brain tissue. Genotyping was performed at Polymorphic DNA Technologies (Alameda, CA) by investigators blinded to all clinical and pathologic data. The APOE genotypes were determined by sequencing rs429358 (codon 112) and rs7412 (codon 158) at exon 4 of the APOE gene.
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Assessment of AD neuropathology
The brains of deceased participants were removed and prepared in a standard procedure, as described previously. [12] [13] [14] The brains were coronally cut into 1-cm slabs, and slabs from one hemisphere were fixed in 4% paraformaldehyde for 3 days. β-Amyloid (Aβ) load and paired helical filament tau immunoreactive neuronal neurofibrillary tangles (tau tangles) were quantified in 8 brain regions (anterior cingulate cortex, superior frontal cortex, midfrontal cortex, inferior temporal cortex, hippocampus, entorhinal cortex, angular gyrus/supramarginal gyrus, and calcarine cortex). Overall Aβ load was calculated by averaging mean percentage area of Aβ deposition per region, across multiple brain regions. Likewise, densities of tangles were derived by averaging densities of tangles across corresponding brain regions. 12 A modified Bielschowsky silver stain was used to visualize neuritic plaques, diffuse plaques, and neurofibrillary tangles in 5 cortical areas (hippocampus, entorhinal, midfrontal, middle temporal, and inferior parietal). A board-certified neuropathologist, blinded to clinical data, determined the pathologic diagnosis of AD based on an intermediate to high likelihood of AD according to National Institute on Aging-Reagan criteria. In addition, a global AD pathology score was determined based on the greatest density of neuritic plaques, diffuse plaques, and neurofibrillary tangles in 1 mm 2 . 15 
Statistical analyses
We stratified participants into 4 groups based on their APOE genotype: e2e4, e2 (e2e2 or e2e3), e4 (e3e4 or e4e4), with e3e3 carriers serving as the reference group.
We first used discrete-time Cox proportional hazards models, adjusted for age, sex, and education, to estimate the association of APOE genotypes with the risk of incident AD dementia. Then, we used the same approach to estimate the APOE association with incident MCI among persons without cognitive impairment at baseline. In both sets of analyses, the outcomes of interest were time in years until the first diagnosis of AD dementia, and separately the first diagnosis of MCI. Participants with no incident event were right censored at the last evaluation, as has been reported previously. 16 In further analyses, we examined the association of APOE genotypes with the rate of cognitive decline. 17 We used linear mixed-effects models to study change in global cognition across years of follow-up. All models also controlled for age, sex, education, and their interaction with annual rate of change in cognition. The models provide 2 sets of estimates. The first set includes an estimate for baseline level of global cognition among the e3e3 carriers and estimates for the differences in baseline global cognition between each of the APOE strata (e2e4, e4, e2) and e3e3 carriers. The second set includes an estimate for average slope of cognitive change among the e3e3 carriers and estimates for the differences in the slope of cognitive changes between each of the APOE strata (e2e4, e4, e2) and e3e3 carriers. In further analyses, we repeated the models to study score changes in cognitive domains (episodic memory, semantic memory, working memory, perceptual speed, and visuospatial ability) among different APOE strata compared with the e3e3 carriers. We subsequently repeated these analyses among persons free of cognitive impairment (NCI) at baseline.
To examine associations of APOE genotypes with Aβ and tau depositions, we used linear regressions, and logistic regression was used to study the association between APOE groups and odds of pathologic AD diagnosis. All of these models also adjusted for age, sex, and education.
Our primary analysis focused on cognition in e2e4 carriers compared to the reference group, e3e3 carriers, so statistical significance was fixed at α level of 0.05. In 2 sets of post hoc comparisons that involved multiple groups (i.e., e2e4 vs e4 and e2e4 vs e2), statistical significance was fixed at α level of 0.025 because of multiple testing. The analyses were done using SAS version 9.4 (SAS Institute, Cary, NC).
Standard protocol approvals, registrations, and patient consents The study was approved by the institutional review board of Rush University Medical Center. Written informed consent and an anatomical gift act for brain donation at the time of death were obtained from all study participants.
Data availability
Anonymized data will be shared by request from any qualified investigator for purposes of replicating procedures and results.
Results
The clinical characteristics of individuals included in these analyses are described more fully in table 1 and appendix e-1 (links.lww.com/WNL/A517). Participants in the analyses (n = 2,151) were, on average, nearly 80 years old at the study baseline, more than 70% female, and had averages of 16 years of education and baseline Mini-Mental State Examination score of 28. The most frequent APOE group was e3e3 (n = 1,335, 62.1%), followed by e4 (n = 469, 21.8%), e2 (n = 301, 14.0%), and e2e4 (n = 46, 2.1%). the results of incident AD dementia (appendix e-3, links.lww. com/WNL/A517).
We next examined the association of e2e4 on the rate of cognitive decline among participants with NCI at baseline, excluding those with MCI. At baseline, the level of global cognition was similar in all APOE groups (table 2, figure 2 ). On average, global cognitive scores declined by 0.067 standard units per year in e3e3 (table 2) . By contrast, the e2e4 carriers showed a 70% more rapid decline in global cognition compared to e3e3 carriers (table 2, figure 2 ). e2e4 carriers also had a more rapid rate of decline in episodic memory, semantic memory, and visuospatial ability, but not for working memory and perceptual speed compared to e3e3 carriers (table 2) .
Among participants with NCI at baseline, there was no significant difference in the rate of cognitive decline between e2e4 and e4 carriers (estimate = −0.007, SE = 0.018, e4 carriers were 3-fold more likely show pathologic AD compared to e3e3 carriers (table 3) . e2 carriers showed a 50% reduced odds of having pathologic AD compared to e3e3 carriers (table 3) .
Compared to e2 carriers, e2e4 carriers had 6.5 times greater odds of a pathologic diagnosis of AD controlling for age, sex, and education. However, no significant difference was found in the odds of a pathologic diagnosis of AD between e2e4 and e4 carriers.
Postmortem AD indices
Appendix e-4 (links.lww.com/WNL/A517) shows boxplots of postmortem indices of AD pathology for APOE genotypes. Using regression models that controlled for age, sex, and education, e2e4 and e4 had higher levels and e2 had lower levels of global AD pathology compared to e3e3 (table 3) . e2e4 and e4 had a higher burden of Aβ and e2 had lower burden of Aβ compared to e3e3. We did not observe significant differences in paired helical filament tau tangle density between e2e4 and e3e3 (table 3) . In contrast, e4 had higher tangle density and e2 had lower tangle density vs e3e3 (table 3) .
Compared to e2, e2e4 carriers had significantly more Aβ deposition and higher burden of global AD pathology and showed a trend for increased tangle density. By contrast, e2e4 carriers had significantly fewer tangles and showed a trend for less global AD pathology compared to e4 carriers, with no significant difference in Aβ deposition.
Discussion
Using data from more than 2,000 older non-Latino white adults without dementia, we found that individuals with the APOE e2e4 genotype had an increased risk of incident MCI and a faster rate of cognitive decline among NCI persons. Abbreviations: AD = Alzheimer disease; CI = confidence interval; OR = odds ratio. Estimates (Est.) are derived from linear regression models β (standard error [SE]) or from logistic regressions OR (95% CI). All the models controlled for age, sex, and education (not shown), and the results in each cell represent the associations for each of the APOE genotypes in each column compared to the reference group e3e3. Figure 2 Relation of APOE genotype with the annual rate of change in global cognition and 5 cognitive abilities during this study among participants with no cognitive impairment at baseline
Moreover, decedents with e2e4 showed increased odds of a pathologic diagnosis of AD and more severe burden of Aβ load but not tau tangle density. By contrast, e4 carriers not only had an increased risk of MCI and more severe burden of Aβ, but they were also more prone to develop AD dementia and had more severe deposition of tau tangle density. In addition, e2 carriers had decreased risk of MCI and AD dementia, slower cognitive decline, and decreased burden of AD brain pathologies compared to e3e3 carriers. These results suggest that despite the presence of a single copy of the e2 allele, which is protective in e2 carriers, adults with the e2e4 genotype manifest an increased risk of late-life cognitive impairment and accumulate a higher burden of AD pathology in the brain in a way that is much more similar to e4 than e2.
Since e2 carriers and e4 carriers are associated with opposite effects and the e2e4 genotype is rare, many previous studies, including those by our group, excluded this variant from prior analyses. 6, 18 Other studies have included few e2e4 carriers without specific analyses for their association with AD dementia. 5, [19] [20] [21] A single cross-sectional, case-control study that examined the association of e2e4 with AD dementia reported no association but included only 18 e2e4 carriers, 22 and a meta-analysis found that e2e4 carriers had an increased odds of AD. 3 Thus, there is a paucity of data about the clinical associations of e2e4 genotype in older adults with late-life cognitive impairment, and we were unable to identify any prior study examining the association of e2e4 with incident MCI, change in cognition, or measures of AD pathology.
Our results were interesting not only for what we found, but also for what we did not find. Despite associations with incident MCI, change in cognition, AD pathology, and Aβ, we did not find an association of e2e4 with risk of incident AD or with rate of cognitive decline when persons with MCI were included in the analyses. Also, we did not find an association of allele status with the density of tau tangles. These data suggest that e2e4 may preferentially affect the early course of AD disease. We previously reported that the effect of Aβ was mediated by tau tangles such that when they are both included in the same model, Aβ is no longer significant. 12, 14 Only when restricting analyses to participants without cognitive impairment did we find associations of Aβ with cognition with tau tangles in the model. 23 Thus, finding an association of e2e4 with incident MCI and Aβ, but not incident AD dementia and tangle density, suggests that the effect of allele status is very early.
Preclinical data suggest that apoE may also be involved in deposition and/or clearance of Aβ from the brain. For example, apoE, and apoE e4 in particular, have been shown to enhance spontaneous fibrillogenesis of Aβ in vitro, 24 and apoE has been found to form complexes with soluble Aβ in AD brains. 25 By using targeted replacement (TR) mice expressing human apoE isoforms, Shinohara et al. 18 showed that memory preservation in apoE e2-TR mice was not related with markers of synaptic integrity, neuroinflammation, or oxidative stress. In contrast, apoE e4-TR mice have been shown to express more systemic and CNS inflammation 26 and more deficits in synaptic integrity 27, 28 than apoE e3-TR mice. These data suggest that the disparate clinical associations of e2 and e4 genotypes may be linked differences in their underlying neurobiology. We found no preclinical study addressing cellular and molecular mechanisms underlying association of e2e4 with cognitive impairment.
The study has several strengths. Uniform structured procedures were followed, examiners were blinded to previously collected data, and all personnel collecting postmortem, genetic, and clinical data were blinded to all other data, further reducing the potential for bias.
Nonetheless, this study has several limitations. Most important, we had only 46 e2e4 carriers in our analytic sample and fewer with the subsample of incident MCI that was small relative to the other more common genotypes, and might account for the high proportion of cases with MCI at baseline and during the course of the study. Although far larger than prior publications, the study will need replicating with even larger samples. Level of education and lifestyles of participants in the study are not representative of the general population. We restricted our analyses to non-Latino white people since previous studies have shown differential associations between APOE genotypes and AD risk in different populations. These studies will need to be extended to other populations. 3 We only quantified the fibrillary form of Aβ and paired helical filament tau-positive tangles by antibodies against single epitopes. It is possible that other epitopes or soluble forms of amyloid or tau are also associated with cognitive decline and risk of AD.
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Study question
Is the APOE e2e4 genotype associated with incident Alzheimer disease (AD), mild cognitive impairment (MCI), cognitive decline, and AD neuropathology in older adults?
Summary answer
The APOE e2e4 genotype is associated with an increased risk of MCI, accelerated cognitive decline, and greater AD neuropathology burdens.
What is known and what this paper adds APOE is the best-known genetic risk determinant of lateonset AD; however, the rare e2e4 genotype has been neglected. The present study clarifies the relationship between this genotype and various AD-related clinical and pathologic manifestations.
Participants and setting
This study examined 2,151 adults from the European ancestry (71.8% women; mean baseline age, 78.3 ± 7.4 years) from the Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP). The ROS has been following members of religious orders at 45 US sites since 1994, and the MAP has been following residents of retirement homes and subsidized housing in Chicago since 1997. All participants were initially dementia-free. The average follow-up period was 7.8 years.
Design, size, and duration APOE sequencing was performed by investigators blinded to clinical data. The participants annually underwent a battery of 21 cognitive tests, and the results were used to detect MCI and AD, as well as to calculate rates of cognitive decline. AD neuropathology was histologically assessed in the brains of participants who died (n = 1,100).
Main results and the role of chance The e2e4 genotype was present in 2.1% of participants, and the e3e3 genotype was present in 62.1% of participants. Compared with e3e3 carriers, e2e4 carriers had faster rates of cognitive decline (β, −0.047 ± 0.018; p = 0.008), an increased risk of incident MCI (hazard ratio, 2.13; 95% confidence interval, 1.34-3.39; p = 0.002), and greater postmortem AD neuropathology burdens. No differences were detected in the AD incidence rate.
Bias, confounding, and other reasons for caution This study included only 46 e2e4 carriers.
Generalizability to other populations
This study only examined white people with lifestyle and education levels unrepresentative of the general population. Therefore, the present findings may not be generalizable to other populations.
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